Des doses plus faibles d'immunothérapie pour le cancer de la peau donnent de meilleurs résultats, conclut cette équipe ...

InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies of its novel BCL2 ...

As the Company prepares for commercialization, RetinalGenix requires a financial, strategic, and operational leader who understands regulated medical devices, clinical development, reimbursement ...

Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles Strong efficacy data support potential advancement to earlier treatment ...

1. About LEQEMBI (generic name: lecanemab, Chinese brand name: 乐意保) ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, ...

CTA311 is an investigational ‘ready-at-point of care’ allogeneic anti-CD19 CAR-T cell therapy designed for B-cell mediated disease. The product candidate incorporates T-cell receptor (TCR) and HLA ...

The abstract can be found on the ASH Annual Meeting website, https://submit.hematology.org/program/presentation/674309 ...

As Arcutis looks to continue to grow in this next chapter, we are delighted to welcome Amit, an exceptional and visionary biopharmaceutical leader, to the Arcutis Board,” said Frank Watanabe, ...

J.P. Morgan, TD Cowen and Piper Sandler acted as joint book-running managers of the offering. LifeSci Capital acted as a lead manager of the offering. H.C. Wainwright & Co. acted as a manager of the ...

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA–restricted, genetically unmodified allogeneic T cells. The ...

Irina Rabovetsky, CEO of A-Team Home Care Inc. About A-Team Home Care Inc.